CA-NOVANTA
NDS, a subsidiary of Novanta Corporation (“Novanta”), is now shipping its new video image management and acquisition solution: VIMA. Intelligently engineered to serve as the backbone of the modern digital integrated operating room (OR), as well as provide the flexibility to function with varying existing procedure rooms and legacy equipment, VIMA brings a new level of versatility to healthcare imaging.
Certified for near patient use, VIMA allows easy and total control of multiple imaging sources. Out-of-the-box functionality provides a procedure-ready solution, receiving up to ten different image sources, and routing instantly to up to eight display destinations. VIMA enables still capture and video recording, with DICOM interface to PACS and HIS systems for secure data archiving. Designed for easy installation and plug-and-play simplicity, VIMA also enables remote teleconference/telemedicine collaboration, and image storage on an encrypted hard drive for enhanced data security.
VIMA offers fingertip control via large format 15” or 21” touch-screen monitors, including a medical-grade option for near patient installation. Easy-to-use, icon-based menus are designed to process rapid commands with a simple touch or swipe from the user, helping to streamline OR workflow. Engineered with a vendor-neutral architecture for versatility, VIMA can be quickly installed in a variety of procedure room environments with limited impact on cabling requirements.
“NDS is committed to providing healthcare professionals with high-value solutions with a focus on simplicity and ease of use,” said Karim Khadr, President and General Manager of NDS. “By simplifying connectivity challenges, and delivering a robust multi-functional imaging solution, VIMA has the potential to positively impact OR workflow and procedure room turnaround.”
HDBaseT technology enabled, the innovative VIMA product offers long-distance uncompressed video transmission up to 100m without compromise in signal integrity. HDBaseT also supports Power over Ethernet (PoE), allowing auxiliary devices to be powered over the same cable used for transmitting video, thereby reducing the number and complexity of connections.
Learn more about the new VIMA integrated OR solution at www.ndssi.com .
About NDS and Novanta
Headquartered in Silicon Valley, California, NDS Surgical Imaging, LLC (NDS) is a global leader in designing and manufacturing endoscopy visualization, video processing, and wireless imaging systems. NDS technology solutions have led the way in re-defining modern operating rooms and endoscopy suites.
At the forefront of innovation in medical imaging technology, NDS delivers HD visualization products that enable the clinical imaging solutions of the future, and drive constant improvements in collaborative medicine. NDS has US-based R&D and manufacturing facilities, and a global presence in more than 35 countries.
Novanta (which trades publicly under its parent entity, Novanta Inc., NASDAQ: NOVT) is a trusted technology partner to original equipment manufacturers in the medical and advanced industrial technology markets, with deep proprietary expertise in photonics, vision and precision motion technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180625006235/en/
Contact:
Novanta
Steven Ross, +1 408-754-4174
steven.ross@ndssi.com
Social Media:
https://www.facebook.com/NDS-Surgical-Imaging-341537195857641/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing9.6.2025 07:00:00 CEST | Press release
Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company’s presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros’ recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating n
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom